Li Zheng Liu

6569638, May 27, 2003

Mar 3, 2000

09/517734

I. Bernard Weinstein - Englewood NJ
W. Joseph Thompson - Doylestown PA
Jae-Won Soh - Cliffside Park NJ
Li Liu - Ambler PA
Han Li - Yardley PA

Cell Pathways, Inc - Horsham PA

C12Q 148

435 15, 435 692, 435184

This invention provides a method to identify compounds potentially useful for the treatment and prevention of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with its ability to elevate JNK kinase activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibition, an ability to elevate JNK kinase activity, growth inhibition and apoptosis induction are desirable for the treatment of neoplasia.

7154670, Dec 26, 2006

Mar 10, 2004

10/796930

Hongbin Zhang - Marlboro NJ, US
Li Liu - Carneys Point NJ, US
R. Brian Jander - Freehold NJ, US
Alexei N. Pilipetskii - Colts Neck NJ, US

Tyco Telecommunications (US) Inc. - Morristown NJ

G02B 27/28

359501, 359497, 385 11

Methods and apparatus of performing polarization control for optical transmissions. The methods and apparatus enable polarization control devices to achieve a desired output state of polarization regardless of the input state of polarization. The desired state of polarization can be achieved by rotating waveplates in a polarization controller in a sequential fashion. Each waveplate may be continually adjusted or dithered so long as the feedback signal satisfies a feedback condition. Once the feedback signal exceeds the feedback condition, the next waveplate in the polarization controller is adjusted. This enables the methods and apparatus to rapidly adjust the state of polarization away from dead spots and minimize loss control problems.

20210404012, Dec 30, 2021

Feb 1, 2021

17/164336

- Leverkusen, DE
- Berlin, DE
Bernard HÄNDLER - Berlin, DE
Sven GOLFIER - Berlin, DE
Andreas SCHLICKER - Berlin, DE
Li LIU - East Hanover NJ, US

Bayer Aktiengesellschaft - Leverkusen
Bayer Pharma Aktiengesellschaft - Berlin

C12Q 1/6886
A61P 35/00
A61K 31/5377

The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject. Preferably the hyper-proliferative disease or the subject is characterized by one or more biomarker(s) selected fromThe present invention also covers a kit comprising Compound A together with means to detect one or more of the aforementioned biomarker(s) and a method for identifying a subject having a hyper-proliferative disease disposed to respond favorably to Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s). Further, the invention covers a method of determining whether a subject having a hyper-proliferative disease will respond to the treatment with Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s) in a sample of the subject.

20200375997, Dec 3, 2020

Dec 4, 2018

16/770462

- Leverkusen, DE
Gerhard SIEMEISTER - Berlin, DE
Li LIU - East Hanover NJ, US

Bayer Aktiengesellschaft - Leverkusen

A61K 31/5377
C12Q 1/6886
A61P 35/00

The present invention covers an ATR kinase inhibitor, particularly 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(H-pyrazol-5-yl)-1,7-naphthyridine (“Compound A”), for use in the treatment of a hyper-proliferative disease in a subject, wherein the hyper-proliferative disease or the subject is or has been characterized by one or more biomarker(s), wherein the biomarker(s) comprise(s) a) one or more functional mutations in one or more gene(s)/protein(s) selected from RBBP8, APOBEC3A, APOBEC3B, CLSPN, ERCC, HUS1, MAD2L2, PGBD5, POLD1, RAD1, TIMELESS and/or TIPIN; and/or b) the expression of a fusion gene encoding a fusion protein selected from EWSR-ERG, EWSR1-FLI1, SS18-SSX and/or SS18-SSX2 gene/protein.

20200063212, Feb 27, 2020

Feb 22, 2018

16/488033

- Leverkusen, DE
- Berlin, DE
Bernard HÄNDLER - Berlin, DE
Sven GOLFIER - Berlin, DE
Andreas SCHLICKER - Berlin, DE
Li LIU - East Hanover NJ, US

Bayer Aktiengesellschaft - Leverkusen
Bayer Pharma Aktiengesellschaft - Berlin

C12Q 1/6886
A61K 31/5377
A61P 35/00

The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyra-zol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject. Preferably the hyper-proliferative disease or the subject is characterized by one or more biomarker(s) selected from a) one or more functional mutation(s) in one or more gene(s)/protein(s) selected from APC, ATG5, ARID1A, ATM, ATR, ATRIP, ATRX, BAP1, BARD1, BLM, BRAF, BRCA1, BRCA2, BRIP1, CCND1, CCNE1, CCNE2, CDC7, CDK12, CHEK1, CHEK2, DCLRE1A, DCLRE1B, DCLRE1C, DYRK1A, EGFR, ERBB2, ERBB3, ERCC2, ERCC3, ERCC4, ER-CC5, FAM175A, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXO18, FBXW7, FEN1, GEN1, HDAC2, H2AFX, HRAS, KRAS, LIG4, MDC1, MLH1, MLH3, MRE11A, MSH2, MSH3, MSH6, MYC, NBN, NRAS, PALB2, PARP1, PARP2, PARP3, PARP4, PCNA, PIK3CA, PMS2, POLA1, POLB, POLH, POLL, POLN, POLQ, PRKDC, PTEN, RAD9A, RAD17, RAD18, RAD50, RAD51, RAD52, RAD54B, RAD54L, RB1, REV3L, RPA1, RPA2, SLX4, TDP1, TDP2, TM-PRSS2, TMPRSS2-ERG, TOPBP1, TOP2A, TOP2B, TP53, TP53BP1, TRRAP, UBE2N, UIMC1, USP1, WDR48, WRN, XPA, XR-CC1 XRCC2, XRCC3, XRCC4 and/or XRCC6 gene/protein; and/or b) the activation of the ALT pathway; and/or c) microsatellite instability. The present invention also covers a kit comprising Compound A together with means to detect one or more of the afore-biomarker(s) and a method for identifying a subject having a hyper-proliferative disease disposed to respond favorably to Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s). Further, the invention covers a method of determining whether a subject having a hyper-proliferative disease will respond to the treatment with Compound A, wherein the method comprises the detection of one or more of the aforementioned biomarker(s) in a sample of the subject.

20190382839, Dec 19, 2019

Jan 31, 2017

16/074037

- Berlin, DE
Li LIU - East Hanover NJ, US
Jie CHENG - Belle Mead NJ, US
Karl KÖCHERT - Potsdam, DE

Bayer Pharma Aktiengesellschaft - Berlin

C12Q 1/6883
G01N 33/68
A61K 31/5377

This invention provides biomarkers based on the gene expression profiling which can discriminate between patients who response to and/or with longer progression free survival and patients who do not response to and/or with shorter progression free survival from copanlisib treatment in lymphoma including indolent and aggressive NHLs and CLLs. The present invention relates to the use of genes from the BCR, PI3K, NFkB, IL6, inflammation and stromal processes as predictive biomarkers for various human cancers including but not limited to NHLs.